Natural Capsules Limited AI Stock Analysis
Want to see IN:NATCAPSUQ full AI Analyst Report?
Natural Capsules Limited (NATCAPSUQ) AI Stock Analysis
Natural Capsules Limited
(NSE:NATCAPSUQ)
The score is primarily constrained by deteriorating profitability and cash generation, with additional pressure from bearish technical momentum and a negative P/E ratio. A relatively solid balance sheet and strong revenue growth provide some support, but they do not yet offset the company’s losses and weak free cash flow.
Natural Capsules Limited (NATCAPSUQ) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 1.45B
- Dividend Yield
- ―
- Average Volume (3M)
- 4,109
- Price to Earnings (P/E)
- -6.6
- Beta (1Y)
- 0.35
- Revenue Growth
- 8.84%
- EPS Growth
- -285.42%
- Country
- India
- Employees
- 620
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Natural Capsules Limited Business Overview & Revenue Model
Company Description
Natural Capsules Ltd. specializes in the production and global distribution of hard gelatin and cellulose capsule shells, catering to markets in India and abroad. The company offers a comprehensive array of capsule types, including those guaranteed f...
Natural Capsules Limited Financial Statement Overview
Summary
Strong revenue growth is offset by sharply deteriorating profitability, negative margins, weak operating cash flow, and increasingly negative free cash flow. The balance sheet remains a partial strength because equity exceeds debt and leverage is manageable.
Income Statement
42NeutralBalance Sheet
63PositiveCash Flow
35Negative| Breakdown | TTM | Mar 2025 | Mar 2024 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 857.19M | 1.87B | 1.64B |
| Gross Profit | 350.75M | 467.09M | 757.25M |
| EBITDA | 39.63M | 1.72M | 182.22M |
| Net Income | -64.68M | -170.74M | 6.17M |
Balance Sheet | |||
| Total Assets | 4.20B | 4.24B | 4.19B |
| Cash, Cash Equivalents and Short-Term Investments | 53.75M | 48.23M | 51.98M |
| Total Debt | 1.12B | 1.15B | 1.05B |
| Total Liabilities | 1.75B | 1.89B | 1.62B |
| Stockholders Equity | 2.27B | 2.22B | 2.33B |
Cash Flow | |||
| Free Cash Flow | -115.70M | -106.77M | -178.78M |
| Operating Cash Flow | 201.52M | 8.53M | 267.52M |
| Investing Cash Flow | -313.49M | -115.30M | -444.85M |
| Financing Cash Flow | 25.08M | 102.16M | 161.67M |
Natural Capsules Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NATCAPSUQ, the sentiment is Negative. The current price of 144.70 is below the 20-day moving average (MA) of 145.27, below the 50-day MA of 163.09, and below the 200-day MA of 158.19, indicating a bearish trend. The MACD of -3.15 indicates Negative momentum. The RSI at 44.41 is Neutral, neither overbought nor oversold. The STOCH value of 67.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:NATCAPSUQ.
Natural Capsules Limited Peers Comparison
Overall Rating
IN:PAR73Outperform
IN:BROOKS61Neutral
IN:BALPHARMA57Neutral
IN:ALPA47Neutral
IN:NATCAPSUQ44Neutral
IN:NECLIFE43Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 73Outperform | INR 1.41B | 10.87 | ― | ― | 9.40% | 34.12% | |
| 61Neutral | INR 2.00B | 2.74 | ― | ― | -14.88% | 431.30% | |
| 57Neutral | INR 1.40B | 17.45 | ― | 1.36% | 18.79% | -2.58% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 47Neutral | INR 1.09B | 30.92 | ― | ― | 0.46% | -83.31% | |
| 44Neutral | INR 1.51B | -6.55 | ― | ― | 8.84% | -285.42% | |
| 43Neutral | INR 1.99B | -3.02 | ― | ― | -99.85% | 78.93% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:NATCAPSUQ | Natural Capsules Limited | 144.70 | -39.05 | -21.25% | |
| IN:ALPA | Alpa Laboratories Limited | 51.60 | -26.88 | -34.25% | |
| IN:BALPHARMA | Bal Pharma Limited | 87.95 | 11.15 | 14.52% | |
| IN:BROOKS | Brooks Laboratories Limited | 67.90 | -35.60 | -34.40% | |
| IN:NECLIFE | Nectar Lifesciences Ltd. | 10.23 | -3.81 | -27.14% | |
| IN:PAR | Par Drugs and Chemicals Limited | 114.80 | 21.97 | 23.67% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 29, 2026
